Telcon RF Pharmaceutical Inc. (200230) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Telcon RF Pharmaceutical Inc. (200230:KRX), powered by AI.

Current Price
₩360
P/E Ratio
-2.2
Market Cap
25.7B
Sector
Healthcare
What is the Telcon RF Pharmaceutical Inc. stock price forecast?

Telcon RF Pharmaceutical Inc. is currently trading at ₩360. View real-time AI analysis on Alpha Lenz.

What is Telcon RF Pharmaceutical Inc. insider trading activity?

View the latest insider trading data for Telcon RF Pharmaceutical Inc. on Alpha Lenz.

What is Telcon RF Pharmaceutical Inc.'s P/E ratio?

Telcon RF Pharmaceutical Inc.'s P/E ratio is -2.2.

Telcon RF Pharmaceutical Inc.

KRX · 200230
₩360+0(+0.00%)Market closedKRX regular session 09:00–15:30 KST
Ask about Telcon RF Pharmaceutical Inc.'s future dividend policy...
Alpha Chat Insight

Telcon RF Pharmaceutical Inc. trades at a P/E of -2.2 (undervalued) with modest ROE of -12.0%. 3Y revenue CAGR of 15.8% highlights clear growth momentum.

Ask for details

Company Overview

Telcon RF Pharmaceutical Inc. is a company operating in the pharmaceutical and health technology sectors. Its primary focus is on the research, development, and commercialization of pharmaceutical products that address a variety of health conditions. The company is known for integrating advanced RF technology into pharmaceutical solutions, aiming to enhance drug delivery and efficacy, which sets it apart in the industry. This innovation positions Telcon RF Pharmaceutical as a significant player in the pharmaceutical industry, where technology increasingly intersects with traditional healthcare models. By concentrating on both domestic and international markets, Telcon RF Pharmaceutical seeks to address a broad spectrum of healthcare needs, thus maintaining a diverse portfolio that is significant for healthcare providers and patients alike. As the company continues to expand its research capabilities and product offerings, it holds a crucial role in advancing healthcare solutions worldwide, contributing to improved patient outcomes and modern healthcare practices.

CEO김지훈
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees124

Company Statistics

FY 2025

Profile

₩25,748,470,800Market Cap
₩43,161,795,160Revenue
7.15MShares Out
124Employees

Margins

23.64%Gross
8.56%EBITDA
1.66%Operating
-26.48%Pre-Tax
-26.48%Net

Valuation

-2.25P/E
0.24P/B
0.60EV/Sales
9.26EV/EBITDA
19.12P/FCF

Growth (CAGR)

15.75%Rev 3Yr
5.43%Rev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-7.37%ROA
-11.97%ROE
-4.27%ROIC

Financial Health

₩26,124,752,790Cash & Cash Equivalents
₩21,725,191,520Net Debt
43.97%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Telcon RF Pharmaceutical Inc. (ticker: 200230) is a company listed on KRX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 124 employees. Market cap is $25.7B.

The current price is ₩360 with a P/E ratio of -2.25x and P/B of 0.24x.

ROE is -11.97% and operating margin is 1.66%. Annual revenue is $43.2B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Telcon RF Pharmaceutical Inc. (200230) Stock Forecast 2026 ₩360 — Price, Financials & Analyst Targets | Alpha Lenz